Conatus Pharmaceuticals Inc. (CNAT) financial statements (2020 and earlier)

Company profile

Business Address 16745 WEST BERNARDO DRIVE
SAN DIEGO, CA 92127
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:21417577373756
Cash and cash equivalents2112165814104
Other undisclosed cash, cash equivalents, and short-term investments 295919232752
Receivables   3   
Other undisclosed current assets1741211
Total current assets:22477980383857
Noncurrent Assets
Property, plant and equipment 000000
Other noncurrent assets0132100
Total noncurrent assets:0132110
TOTAL ASSETS:22498282403857
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:16125331
Employee-related liabilities0222111
Other undisclosed accounts payable and accrued liabilities14103120
Debt0  1   
Deferred revenue and credits1431   
Contract with customer, liability10
Other undisclosed current liabilities0222111
Total current liabilities:2192840443
Noncurrent Liabilities
Long-term debt and lease obligation  13 111
Long-term debt, excluding current maturities  13 111
Liabilities, other than long-term debt 3132100 
Deferred revenue and credits132100 
Contract with customer, liability3
Deferred rent credit 0
Total noncurrent liabilities: 32621111
Total liabilities:2215461554
Stockholders' equity
Stockholders' equity attributable to parent, including:20272822353353
Common stock0000000
Additional paid in capital218214196172155130128
Accumulated other comprehensive income (loss) (0)(0)(0)(0)(0)0
Accumulated deficit(198)(187)(168)(151)(121)(97) 
Other undisclosed stockholders' equity attributable to parent      (74)
Total stockholders' equity:20272822353353
TOTAL LIABILITIES AND EQUITY:22498282403857

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Gross profit:2234351   
Operating expenses(34)(52)(53)(31)(24)(22)(12)
Operating loss:(12)(18)(18)(30)(24)(22)(12)
Nonoperating income (expense)1000(0)(0)(4)
Investment income, nonoperating11100(1)(0)
Other nonoperating income (expense)00(0)0(0)(0)(0)
Interest and debt expense (1)(1)(0)(0)(0)(0)
Loss before gain (loss) on sale of properties:(11)(19)(18)(30)(24)(22)(16)
Other undisclosed net income 1     
Net loss:(11)(18)(18)(30)(24)(22)(16)
Other undisclosed net income attributable to parent  10000
Net loss attributable to parent:(11)(18)(17)(30)(24)(22)(16)
Other undisclosed net income available to common stockholders, basic      11
Net loss available to common stockholders, diluted:(11)(18)(17)(30)(24)(22)(5)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(11)(18)(18)(30)(24)(22)(16)
Comprehensive loss:(11)(18)(18)(30)(24)(22)(16)
Other undisclosed comprehensive income, net of tax, attributable to parent0010000
Comprehensive loss, net of tax, attributable to parent:(11)(18)(17)(30)(24)(22)(16)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: